NCT02935790View on ClinicalTrials.gov

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

April 7, 2017

Study Completion Date

April 7, 2017

Conditions
Malignant Melanoma
Interventions
DRUG

ACY-241

tablet

DRUG

nivolumab

infusion

DRUG

ipilimumab

infusion

Trial Locations (1)

10016

NYU Langone Medical Center, New York

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

ApoCell, Inc.

INDUSTRY

collaborator

Celerion

INDUSTRY

collaborator

NYU Langone Health

OTHER

lead

Celgene

INDUSTRY

NCT02935790 - Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | Biotech Hunter | Biotech Hunter